Holen Sie sich die Stockscreener-App
26.76
0.69%
-0.097
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance Singapore
Pfizer's Top Legal Officer Nets Almost $2.3M More In 2025 - Law360
Lobbying Update: $2,870,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Self-represented worker’s 64-page Pfizer claim struck for violating pleading rules - HR Law Canada
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline - TipRanks
How Investors Are Reacting To Pfizer (PFE) Phase 2 Win For Tilrekimig In Atopic Dermatitis - simplywall.st
Form DEF 14A PFIZER INC For: Apr 23 - StreetInsider
The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income - Barchart.com
Franklin Resources Inc. Raises Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Mackenzie Financial Corp Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer’s Weight Management Drug Wins China Approval - Insider Monkey
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case - Reuters
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Pfizer streamlines LC/UV/MS data processing, analysis and reporting - Chromatography Today
Improving method transfer: How Pfizer uses method development software - Chromatography Today
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study - TipRanks
Dilated Cardiomyopathy Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Bristol Myers Squibb, Berlin Cures, Cumberland Pharma, Vericel Corp, Corimmun GmbH, Pfizer, Constant Therapeut - Barchart.com
One Pediatric Gastroenterologist’s Mission to Expand Pediatric Treatment Options - Pfizer
651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA - MarketBeat
Nasal Vaccines Market Is Going to Boom Rapidly | Pfizer • Moderna • GlaxoSmithKline - openPR.com
Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc.: No turn-around in sight - marketscreener.com
Pfizer Stock: Cheap For A Reason (NYSE:PFE) - Seeking Alpha
Pfizer’s Comirnaty update: what the new COVID shot really means for you - AD HOC NEWS
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Self -Care for Caregivers - Pfizer
PFIZER INC : UBS is Neutral - marketscreener.com
GIPR antagonists reported in Pfizer patent - bioworld.com
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity - FinancialContent
Van ECK Associates Corp Sells 4,744,499 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE): Impact from BioNTech Partnership in 2026 - GuruFocus
Legal & General Group Plc Purchases 3,296,415 Shares of Pfizer Inc. $PFE - MarketBeat
Banque Cantonale Vaudoise Sells 92,252 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Swiss National Bank Trims Stake in Pfizer Inc. $PFE - MarketBeat
562,908 Shares in Pfizer Inc. $PFE Bought by WINTON GROUP Ltd - MarketBeat
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Reuters
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Pfizer’s tilrekimig meets Phase 2 trial endpoint for dermatitis - Investing.com India
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
Anti Infective Vaccines Market Witnessing Massive Growth - openPR.com
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Is Pfizer Inc. stock gaining market share2025 Bull vs Bear & Community Consensus Trade Signals - Naître et grandir
Neuberger Berman Group LLC Grows Stock Position in Pfizer Inc. $PFE - MarketBeat
American Century Companies Inc. Sells 546,598 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Obesity Nod In China And Cancer Wins Reframe Long Term Growth - Yahoo Finance
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
China Clears Weight-Loss Shot As Pfizer Enters Crowded Market - Benzinga
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
0.32%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):